BRPI0710645A2 - Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos - Google Patents
Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos Download PDFInfo
- Publication number
- BRPI0710645A2 BRPI0710645A2 BRPI0710645-9A BRPI0710645A BRPI0710645A2 BR PI0710645 A2 BRPI0710645 A2 BR PI0710645A2 BR PI0710645 A BRPI0710645 A BR PI0710645A BR PI0710645 A2 BRPI0710645 A2 BR PI0710645A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein tyrosine
- human protein
- hptpbeta
- tyrosine phosphatase
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Abstract
ANTICORPOS QUE SE LIGAM à PROTEìNA HUMANA TIROSINA FOSFATASE BETA (HPTPBETA) E USOS DOS MESMOS. A presente invenção refere-se a anticorpos e fragmentos de ligação a antígeno desses anticorpos que se ligam à proteína humana tirosina fosfatase beta (HPTPâ) e aos usos dos mesmos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79050606P | 2006-04-07 | 2006-04-07 | |
US60/790,506 | 2006-04-07 | ||
US79889606P | 2006-05-09 | 2006-05-09 | |
US60/798,896 | 2006-05-09 | ||
PCT/IB2007/051239 WO2007116360A2 (en) | 2006-04-07 | 2007-04-05 | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0710645A2 true BRPI0710645A2 (pt) | 2012-03-20 |
Family
ID=38325438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0710645-9A BRPI0710645A2 (pt) | 2006-04-07 | 2007-04-05 | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos |
Country Status (20)
Country | Link |
---|---|
US (6) | US7973142B2 (pt) |
EP (3) | EP3252079B8 (pt) |
JP (6) | JP5166398B2 (pt) |
KR (3) | KR101482483B1 (pt) |
CN (2) | CN101802002B (pt) |
AU (1) | AU2007237096C1 (pt) |
BR (1) | BRPI0710645A2 (pt) |
CA (1) | CA2648284C (pt) |
DK (1) | DK2371865T3 (pt) |
ES (2) | ES2828739T3 (pt) |
IL (3) | IL194550A (pt) |
MA (1) | MA30353B1 (pt) |
MX (1) | MX2008012991A (pt) |
MY (1) | MY150400A (pt) |
NZ (1) | NZ571300A (pt) |
PL (1) | PL2371865T3 (pt) |
PT (1) | PT2371865T (pt) |
RU (2) | RU2473565C2 (pt) |
SM (1) | SMP200800060B (pt) |
WO (1) | WO2007116360A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2371865T3 (pl) | 2006-04-07 | 2018-02-28 | Aerpio Therapeutics, Inc. | Przeciwciała wiążące ludzką białkową fosfatazę tyrozynową beta (HPTP-β) oraz ich zastosowania |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US9074002B2 (en) * | 2009-04-27 | 2015-07-07 | Cold Spring Harbor Laboratory | PTP1B inhibitors |
SG172313A1 (en) | 2009-07-06 | 2011-07-28 | Akebia Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
MX2012005275A (es) | 2009-11-06 | 2012-06-19 | Aerpio Therapeutics Inc | Composiciones y metodos para tratar colitis. |
US20120129847A1 (en) * | 2010-10-07 | 2012-05-24 | Kevin Gene Peters | Compositions and methods for treating ocular edema, neovascularization and related diseases |
JP2013051957A (ja) * | 2011-08-08 | 2013-03-21 | National Institutes Of Natural Sciences | 受容体型チロシンホスファターゼPtprbを用いた受容体型チロシンキナーゼの活性抑制 |
CN107080843A (zh) * | 2011-10-13 | 2017-08-22 | 爱尔皮奥治疗有限公司 | 眼病的治疗 |
EP2766043A4 (en) * | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
CA2903871A1 (en) * | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Formulations with increased solubility of compounds that activate tie-2 |
EP2835380B2 (en) | 2013-07-29 | 2021-04-07 | Samsung Electronics Co., Ltd | Method of blocking vascular leakage using an anti-Ang2 antibody |
KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
EP3107542B1 (en) | 2014-02-19 | 2019-05-01 | Aerpio Therapeutics, Inc. | Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones |
EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
CA2998673C (en) | 2015-09-23 | 2023-12-12 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
US20190023806A1 (en) * | 2015-10-21 | 2019-01-24 | Qoolabs, Inc. | Camelid hemoglobin antibodies and methods of use |
WO2018017714A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
JP2022530657A (ja) | 2019-04-29 | 2022-06-30 | アイポイント ファーマシューティカルズ, インコーポレイテッド | シュレム管を標的とするTie-2活性化物質 |
GB2589400A (en) | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
Family Cites Families (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4673641A (en) * | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
ES2298325T3 (es) * | 1992-03-13 | 2008-05-16 | Biomerieux B.V. | Peptidos y secuencias de acido nucleico relacionadas con el virus epstein barr. |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
US5688781A (en) * | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
ATE273384T1 (de) | 1995-04-06 | 2004-08-15 | Regeneron Pharma | Tie-2 liganden, herstellungsverfahren und verwendung |
US5994128A (en) * | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
AU5154098A (en) | 1996-10-31 | 1998-05-22 | Duke University | Soluble tie2 receptor |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
AR022303A1 (es) * | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
DE60003011T2 (de) | 1999-03-26 | 2004-04-08 | Regeneron Pharmaceuticals, Inc. | Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren |
EP1046715A1 (en) * | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
AU5062500A (en) | 1999-04-26 | 2000-11-10 | Amersham Pharmacia Biotech Ab | Primers for identifying typing or classifying nucleic acids |
ATE269357T1 (de) * | 1999-04-28 | 2004-07-15 | Univ Texas | Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf |
WO2000070030A1 (en) * | 1999-05-19 | 2000-11-23 | Amgen Inc. | Crystal of a lymphocyte kinase-ligand complex and methods of use |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
AU775625B2 (en) | 1999-08-27 | 2004-08-05 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
WO2001064944A1 (en) * | 2000-02-29 | 2001-09-07 | Barnes-Jewish Hospital | MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
US6589758B1 (en) * | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
KR20030036238A (ko) | 2000-06-23 | 2003-05-09 | 쉐링 악티엔게젤샤프트 | VEGF/VEGF 수용체 및 안지오포이에틴/Tie수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ) |
US6316109B1 (en) | 2000-09-21 | 2001-11-13 | Ppg Industries Ohio, Inc. | Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers |
CA2420045A1 (en) | 2000-09-27 | 2002-04-04 | The Procter & Gamble Company | Melanocortin receptor ligands |
CA2439630A1 (en) * | 2001-03-23 | 2002-10-03 | Agy Therapeutics | Use of biomolecular targets in the treatment and visualization of brain tumors |
US6455026B1 (en) * | 2001-03-23 | 2002-09-24 | Agy Therapeutics, Inc. | Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors |
CN1318093C (zh) | 2001-09-28 | 2007-05-30 | 参天制药株式会社 | 含与聚乙二醇结合的药物的眼组织注射剂 |
US20050260132A1 (en) * | 2001-10-17 | 2005-11-24 | Daniel Chin | Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta |
WO2003034990A2 (en) | 2001-10-25 | 2003-05-01 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
EP1450852B1 (en) * | 2001-12-04 | 2007-01-17 | DeveloGen Aktiengesellschaft | Ptp10d nucleic acids and peptides involved in the regulation of energy homeostasis |
US20030158083A1 (en) | 2002-02-08 | 2003-08-21 | The Procter & Gamble Company | Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase |
US20030215899A1 (en) | 2002-02-13 | 2003-11-20 | Ceptyr, Inc. | Reversible oxidation of protein tyrosine phosphatases |
AU2003229627A1 (en) | 2002-04-08 | 2003-10-20 | Max-Planck-Gesellschaft Zur | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
CA2483449A1 (en) | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
WO2003092611A2 (en) | 2002-05-03 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of inducing formation of functional and organized lymphatic vessels |
US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
US20050154011A1 (en) * | 2003-02-20 | 2005-07-14 | The Procter & Gamble Company | Tetrahydroisoquinolnyl sulfamic acids |
WO2004106542A1 (ja) | 2003-05-29 | 2004-12-09 | Sankyo Company, Limited | インスリン抵抗性改善剤及びそのスクリーニング方法 |
AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
US20050158320A1 (en) | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
EP2298744B1 (en) | 2004-03-15 | 2013-06-26 | Janssen Pharmaceutica NV | Opioid receptor modulators |
US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
PT1771474E (pt) | 2004-07-20 | 2010-05-03 | Genentech Inc | Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização |
EP2457578B1 (en) | 2004-09-28 | 2015-08-19 | Aprogen, Inc. | Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
AU2005327973A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
US20120237442A1 (en) | 2005-04-06 | 2012-09-20 | Ibc Pharmaceuticals, Inc. | Design and Construction of Novel Multivalent Antibodies |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
KR200400225Y1 (ko) | 2005-08-02 | 2005-11-03 | 김기룡 | 자동복귀 기능을 가지는 도로교통표지판 어셈브리 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
CA2622772A1 (en) | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
FR2894225B1 (fr) | 2005-12-07 | 2008-01-11 | Airbus France Sa Sa | Mur de cloisonnement pour carenage ventral d'aeronef et aeronef muni d'un carenage ventral |
FR2894536B1 (fr) | 2005-12-09 | 2009-10-09 | Holophane Sa Sa | Retroviseur de vehicule automobile |
FR2894517B1 (fr) | 2005-12-09 | 2010-01-08 | Renault | Systeme de surveillance de la pression des pneumatiques d'un vehicule automobile et procede pour etablir un diagnostic au moyen de ce systeme |
EP2518083A3 (en) | 2005-12-15 | 2012-12-05 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer |
CA2622312A1 (en) | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
US7588924B2 (en) * | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
KR101584468B1 (ko) | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-c5 제제 |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
PL2371865T3 (pl) | 2006-04-07 | 2018-02-28 | Aerpio Therapeutics, Inc. | Przeciwciała wiążące ludzką białkową fosfatazę tyrozynową beta (HPTP-β) oraz ich zastosowania |
ZA200807978B (en) | 2006-04-07 | 2009-08-26 | Procter & Gamble | Antibodies that bind human protein tyrosine phosphatase beta (HPTPBETA) and uses thereof |
SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
RU2435763C2 (ru) | 2006-06-27 | 2011-12-10 | Дзе Проктер Энд Гэмбл Компани | Ингибиторы тирозинфосфатазы белка человека и способы применения |
CN101506180B (zh) | 2006-06-27 | 2013-10-30 | 艾尔普罗医疗有限公司 | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US7733204B2 (en) | 2006-06-29 | 2010-06-08 | Intel Corporation | Configurable multiphase coupled magnetic structure |
IL176666A0 (en) | 2006-07-02 | 2006-10-31 | Rol Profil Ltd | Roller shutter assembly |
IL176685A (en) | 2006-07-03 | 2011-02-28 | Eci Telecom Dnd Inc | Method for performing a system shutdown |
IL176712A0 (en) | 2006-07-05 | 2007-10-31 | Michael Cohen Alloro | Medication dispenser |
DK2076290T3 (en) | 2006-10-27 | 2017-01-23 | Sunnybrook Health Sciences Center | MULTIMERIC TIE 2 AGONISTS AND APPLICATIONS THEREOF IN STIMULATING ANGIOGENESIS |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
MX2009010699A (es) | 2007-04-03 | 2010-03-10 | Novartis Ag | Nuevos metodos. |
US20100256147A1 (en) | 2007-04-13 | 2010-10-07 | Hangauer Jr David G | Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
EP2176294B1 (en) | 2007-06-29 | 2015-05-20 | Merck Sharp & Dohme Corp. | Uses of mdl-1 antagonists |
CN101918579A (zh) | 2007-10-22 | 2010-12-15 | 先灵公司 | 完全人抗-vegf抗体和使用方法 |
EP2280601A4 (en) | 2008-02-21 | 2012-08-29 | Sequoia Pharmaceuticals Inc | AMINO ACID HEMMER OF CYTOCHROM P450 |
US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
EP3722310A1 (en) | 2008-06-25 | 2020-10-14 | Novartis AG | Stable and soluble antibodies inhibiting vegf |
US7769557B2 (en) * | 2008-07-01 | 2010-08-03 | Honeywell International Inc. | Multi-gas flow sensor with gas specific calibration capability |
KR101698362B1 (ko) | 2008-11-03 | 2017-01-20 | 몰리큘라 파트너스 아게 | Vegf-a 수용체 상호작용을 억제하는 결합 단백질 |
US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
RU2539917C2 (ru) | 2009-01-12 | 2015-01-27 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
KR20160135372A (ko) | 2009-03-03 | 2016-11-25 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(RTKi) 화합물을 눈에 전달하기 위한 약학 조성물 |
MX2011008680A (es) | 2009-03-03 | 2011-09-08 | Alcon Res Ltd | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. |
SG172313A1 (en) | 2009-07-06 | 2011-07-28 | Akebia Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
MX2012005275A (es) | 2009-11-06 | 2012-06-19 | Aerpio Therapeutics Inc | Composiciones y metodos para tratar colitis. |
CN102753194B (zh) | 2009-12-02 | 2015-07-08 | 伊麦吉纳博公司 | 靶向人前列腺特异性膜抗原的j591微抗体和双抗体 |
WO2011087066A1 (ja) | 2010-01-14 | 2011-07-21 | 株式会社三和化学研究所 | 眼内血管新生及び/又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
CA2791383C (en) | 2010-03-05 | 2022-09-20 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
KR20130045341A (ko) | 2010-07-12 | 2013-05-03 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여 |
US20120129847A1 (en) | 2010-10-07 | 2012-05-24 | Kevin Gene Peters | Compositions and methods for treating ocular edema, neovascularization and related diseases |
US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
CN103249422A (zh) | 2010-12-02 | 2013-08-14 | 丸善制药株式会社 | Tie2活化剂、血管内皮生长因子抑制剂、血管生成抑制剂、血管成熟剂、血管正常化剂及血管稳定剂、以及药物组合物 |
KR20200077622A (ko) | 2011-01-13 | 2020-06-30 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
CN107080843A (zh) | 2011-10-13 | 2017-08-22 | 爱尔皮奥治疗有限公司 | 眼病的治疗 |
EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
EP2773670A4 (en) | 2011-11-03 | 2015-09-02 | Tolera Therapeutics Inc | ANTIBODIES AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES |
US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
US20150071941A1 (en) | 2012-04-13 | 2015-03-12 | The Johns Hopkins University | Treatment of ischemic retinopathies |
EP2846836B1 (en) | 2012-05-07 | 2019-08-14 | Allergan, Inc. | Method of treating amd in patients refractory to anti-vegf therapy |
LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
WO2014022455A1 (en) | 2012-07-31 | 2014-02-06 | The Board Of Regents Of The University Of Texas System | Methods and compositions for in vivo induction of pancreatic beta cell formation |
US20150297675A1 (en) | 2012-08-28 | 2015-10-22 | Aaron Osborne | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
MY177912A (en) | 2012-10-11 | 2020-09-25 | Ascendis Pharma Ophthalmology Div A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
KR20210133321A (ko) | 2012-11-08 | 2021-11-05 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
EP2922572A1 (en) | 2012-11-23 | 2015-09-30 | AB Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
CA2903871A1 (en) | 2013-03-15 | 2014-09-18 | Aerpio Therapeutics Inc. | Formulations with increased solubility of compounds that activate tie-2 |
DK2983695T3 (da) | 2013-04-11 | 2019-09-02 | Sunnybrook Res Inst | Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister |
US20160130321A1 (en) | 2013-06-20 | 2016-05-12 | Gabriela Burian | Use of a vegf antagonist in treating macular edema |
JP2016522249A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるvegfアンタゴニストの使用 |
WO2015002893A1 (en) | 2013-07-02 | 2015-01-08 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
BR112016000282A2 (pt) | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
CA2917807A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
EP2835380B2 (en) | 2013-07-29 | 2021-04-07 | Samsung Electronics Co., Ltd | Method of blocking vascular leakage using an anti-Ang2 antibody |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
TR201905773T4 (tr) | 2013-10-01 | 2019-05-21 | Sphingotec Gmbh | Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul. |
US9968674B2 (en) | 2013-10-18 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody |
PL3062811T3 (pl) | 2013-11-01 | 2019-10-31 | Regeneron Pharma | Interwencje oparte na angiopoetynie do leczenia malarii mózgowej |
EP3628324A1 (en) | 2013-11-05 | 2020-04-01 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
MX2016009047A (es) | 2014-01-10 | 2017-04-13 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (il-33). |
EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
JP2015199733A (ja) | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
US9403913B2 (en) | 2014-09-16 | 2016-08-02 | Ovascience, Inc. | Anti-VASA antibodies, and methods of production and use thereof |
US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
HRP20220066T1 (hr) | 2014-12-11 | 2022-04-15 | Bayer Healthcare Llc | Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom |
WO2016115092A1 (en) | 2015-01-12 | 2016-07-21 | La Jolla Institute For Allergy And Immunology | Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever |
EP4272838A3 (en) | 2015-04-02 | 2024-01-10 | Molecular Partners AG | Designed ankyrin repeat domains with binding specificity for serum albumin |
WO2017035430A2 (en) | 2015-08-27 | 2017-03-02 | Kolltan Pharmaceuticals, Inc. | Anti-alk antibodies and methods for use thereof |
CN108137681A (zh) | 2015-09-23 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
CA2998673C (en) | 2015-09-23 | 2023-12-12 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
EP3432927A4 (en) | 2016-03-24 | 2019-11-20 | Gensun Biopharma Inc. | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT |
EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
WO2018017714A1 (en) * | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
EP3522906B1 (en) | 2016-10-04 | 2022-03-23 | Asclepix Therapeutics, Inc. | Compounds and methods for activating tie2 signaling |
IT201600120314A1 (it) | 2016-11-28 | 2018-05-28 | Nuovo Pignone Tecnologie Srl | Turbo-compressore e metodo di funzionamento di un turbo-compressore |
US10426817B2 (en) | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
US20200140547A1 (en) | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
CN107602702A (zh) | 2017-09-22 | 2018-01-19 | 生标(上海)医疗器械科技有限公司 | 一种同时靶向人p185和血管内皮生长因子的抗体及其应用 |
PL3716992T3 (pl) | 2017-11-30 | 2022-12-19 | Regeneron Pharmaceuticals, Inc. | Zastosowanie antagonisty vegf do leczenia angiogennych zaburzeń oka |
EP3758735B1 (en) | 2018-02-28 | 2023-12-13 | AP Biosciences, Inc. | Bifunctional proteins combining checkpoint blockade for targeted therapy |
CA3091096A1 (en) | 2018-03-16 | 2019-09-19 | Novartis Ag | Methods for treating ocular diseases |
US10276202B1 (en) | 2018-04-23 | 2019-04-30 | Western Digital Technologies, Inc. | Heat-assisted magnetic recording (HAMR) medium with rhodium or rhodium-based alloy heat-sink layer |
SG11202010684YA (en) | 2018-05-10 | 2020-11-27 | Regeneron Pharma | High concentration vegf receptor fusion protein containing formulations |
CA3100349A1 (en) | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
US11066476B2 (en) | 2018-09-14 | 2021-07-20 | Shanghai tongji hospital | Asymmetric bispecific antibody |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
-
2007
- 2007-04-05 PL PL11155518T patent/PL2371865T3/pl unknown
- 2007-04-05 BR BRPI0710645-9A patent/BRPI0710645A2/pt not_active Application Discontinuation
- 2007-04-05 RU RU2008138399/10A patent/RU2473565C2/ru not_active IP Right Cessation
- 2007-04-05 CN CN200780011778.0A patent/CN101802002B/zh active Active
- 2007-04-05 SM SM200800060T patent/SMP200800060B/it unknown
- 2007-04-05 ES ES17169315T patent/ES2828739T3/es active Active
- 2007-04-05 KR KR1020137022106A patent/KR101482483B1/ko active IP Right Grant
- 2007-04-05 KR KR1020117024995A patent/KR20110122881A/ko not_active Application Discontinuation
- 2007-04-05 JP JP2009503719A patent/JP5166398B2/ja not_active Expired - Fee Related
- 2007-04-05 RU RU2011141686/10A patent/RU2494108C2/ru not_active IP Right Cessation
- 2007-04-05 PT PT111555181T patent/PT2371865T/pt unknown
- 2007-04-05 US US11/784,094 patent/US7973142B2/en active Active
- 2007-04-05 KR KR1020087026944A patent/KR20080113275A/ko active Search and Examination
- 2007-04-05 DK DK11155518.1T patent/DK2371865T3/en active
- 2007-04-05 AU AU2007237096A patent/AU2007237096C1/en active Active
- 2007-04-05 CA CA2648284A patent/CA2648284C/en active Active
- 2007-04-05 NZ NZ571300A patent/NZ571300A/en unknown
- 2007-04-05 CN CN201610648805.6A patent/CN106046166A/zh active Pending
- 2007-04-05 EP EP17169315.3A patent/EP3252079B8/en active Active
- 2007-04-05 ES ES11155518.1T patent/ES2643469T3/es active Active
- 2007-04-05 WO PCT/IB2007/051239 patent/WO2007116360A2/en active Application Filing
- 2007-04-05 EP EP11155518.1A patent/EP2371865B1/en active Active
- 2007-04-05 MY MYPI20083870 patent/MY150400A/en unknown
- 2007-04-05 MX MX2008012991A patent/MX2008012991A/es active IP Right Grant
- 2007-04-05 EP EP07735408A patent/EP2004697A2/en not_active Withdrawn
-
2008
- 2008-10-06 IL IL194550A patent/IL194550A/en active IP Right Grant
- 2008-10-23 MA MA31325A patent/MA30353B1/fr unknown
-
2011
- 2011-05-25 US US13/115,180 patent/US8524235B2/en active Active
-
2012
- 2012-10-05 JP JP2012223157A patent/JP2013047240A/ja active Pending
-
2013
- 2013-08-05 US US13/958,990 patent/US20140044707A1/en not_active Abandoned
-
2015
- 2015-05-27 JP JP2015107275A patent/JP2015155466A/ja active Pending
- 2015-06-10 IL IL239320A patent/IL239320B/en active IP Right Grant
-
2016
- 2016-11-22 JP JP2016226664A patent/JP6395791B2/ja active Active
-
2017
- 2017-02-10 US US15/430,100 patent/US9926367B2/en active Active
- 2017-07-04 JP JP2017131042A patent/JP2017186365A/ja active Pending
-
2018
- 2018-02-12 US US15/894,442 patent/US20190023773A1/en not_active Abandoned
- 2018-12-17 IL IL263755A patent/IL263755A/en unknown
- 2018-12-28 JP JP2018246735A patent/JP2019048896A/ja active Pending
-
2020
- 2020-02-07 US US16/784,970 patent/US11814425B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0710645A2 (pt) | Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos | |
BR112013021562A2 (pt) | anticorpos para cd70 | |
CL2008003561A1 (es) | Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias. | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
BRPI0812913A8 (pt) | Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos | |
TR201910348T4 (tr) | Matriks metalloproteinaz 9 için antikorlar. | |
BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
ECSP11011445A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b | |
UY33319A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
CO7250445A2 (es) | Proteínas de unión a antígeno st2 | |
CL2012003245A1 (es) | Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp. | |
CR20120210A (es) | Proteínas de enlace al antigeno il-23 humanas | |
CO6311003A2 (es) | Proteinas de union a la proteina rgm a, sus construcciones y conjugados de anticuerpos monoclonales contra la proteina rgm a | |
BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
BRPI0611414B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos | |
EA201291181A1 (ru) | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
MX2010006767A (es) | Anticuerpos de virus de hepatitis c. | |
CL2011003354A1 (es) | Proteina de union a antigeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a adamts5 humana; polinucleotido aislado que la codifica; celula huesped; composicion farmaceutica; y su uso para tratar enfermedades del cartilago. | |
BR112014021477A2 (pt) | anticorpos para metaloproteinase de matriz 9 | |
BR112018007318A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição. | |
BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
BR112012010266A2 (pt) | anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo | |
BR112017021484A2 (pt) | anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos | |
BR112015012708A2 (pt) | anticorpos para bmp-6 | |
BR112014029219A8 (pt) | moléculas de ligação de il-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: WARNER CHILCOTT COMPANY, LLC (PR) |
|
B25A | Requested transfer of rights approved |
Owner name: AKEBIA THERAPEUTICS INC. (US) |
|
B25A | Requested transfer of rights approved |
Owner name: AERPIO THERAPEUTICS INC. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |